Sionna Therapeutics Ownership | Who Owns Sionna Therapeutics?


OverviewFinancialsChart

Sionna Therapeutics Ownership Summary


Sionna Therapeutics is owned by 15.10% institutional investors, 6.93% insiders, and 77.98% retail investors. Ra capital management is the largest institutional shareholder, holding 23.68% of SION shares.

SION Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSionna Therapeutics15.10%6.93%77.98%
SectorHealthcare Stocks 232.20%10.74%-142.94%
IndustryBiotech Stocks 382.11%10.55%-292.66%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management10.45M23.68%$307.20M
Tpg gp a6.74M15.29%$198.37M
Orbimed advisors3.70M8.40%$108.96M
Atlas venture life science advisors3.62M8.20%$106.33M
Viking global investors lp3.20M7.24%$93.97M
Enavate sciences gp2.48M5.62%$72.88M
Blackrock funding, inc. /de1.29M2.90%$53.14M
Jpmorgan chase1.23M2.77%$50.68M
Perceptive advisors1.18M2.67%$34.68M
Vanguard group1.18M2.67%$48.75M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Enavate sciences gp2.48M22.25%$72.88M
Atlas venture life science advisors3.62M14.13%$106.33M
Tpg gp a6.74M10.80%$198.37M
Ra capital management10.45M3.79%$307.20M
Orbimed advisors3.70M2.57%$108.96M
Perceptive advisors1.18M1.00%$34.68M
Deerfield management company, l.p. (series c)970.59K0.44%$28.55M
Soleus capital management268.50K0.41%$11.05M
Siren325.00K0.37%$9.56M
Braidwell lp314.01K0.27%$9.24M

Top Buyers

HolderShares% AssetsChange
State street693.39K0.00%453.20K
Blackrock funding, inc. /de1.29M0.00%446.99K
Jennison associates1.12M0.03%117.90K
Ensign peak advisors79.86K0.01%79.86K
Geode capital management380.04K0.00%63.48K

Top Sellers

HolderShares% AssetsChange
Braidwell lp314.01K0.27%-767.84K
Jpmorgan chase1.23M0.00%-746.81K
Zimmer partners, lp---237.50K
Price t rowe associates inc /md/637.76K0.00%-223.48K
Soleus capital management268.50K0.41%-145.00K

New Positions

HolderShares% AssetsChangeValue
Ensign peak advisors79.86K0.01%79.86K$3.29M
Longaeva partners61.46K0.26%61.46K$1.81M
Seven grand managers50.00K0.16%50.00K$2.06M
Wellington management group llp42.23K0.00%42.23K$1.24M
Alps advisors36.65K0.01%36.65K$1.51M

Sold Out

HolderChange
Srs capital advisors-92.00
Federated hermes-113.00
Strs ohio-2.30K
Two sigma investments, lp-11.71K
Balyasny asset management-13.06K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202540-48.72%6,711,927-84.33%150.16%29-25.64%7-63.16%
Sep 30, 202529-55.38%6,672,182-84.64%150.16%18-59.09%6-40.00%
Jun 30, 20256538.30%43,448,3954.72%980.40%44-6.38%10-
Mar 31, 202547-41,491,947-156-47---

Recent Insider Transactions


DateNameRoleActivityValue
Feb 02, 2026Thompson Peter A.-Sell$84.24K
Feb 03, 2026Thompson Peter A.-Sell$1.30M
Feb 03, 2026ORBIMED ADVISORS LLC-Sell$1.30M
Feb 02, 2026ORBIMED ADVISORS LLC-Sell$84.24K
Jan 22, 2026TPG GP A, LLC-Sell$10.00M

Insider Transactions Trends


DateBuySell
2026 Q1-5
2025 Q4-112
2025 Q3-17
2025 Q21-

SION Ownership FAQ


Who Owns Sionna Therapeutics?

Sionna Therapeutics shareholders are primarily institutional investors at 15.10%, followed by 6.93% insiders and 77.97% retail investors. The average institutional ownership in Sionna Therapeutics's industry, Biotech Stocks , is 382.11%, which Sionna Therapeutics falls below.

Who owns the most shares of Sionna Therapeutics?

Sionna Therapeutics’s largest shareholders are Ra capital management (10.45M shares, 23.68%), Tpg gp a (6.74M shares, 15.29%), and Orbimed advisors (3.7M shares, 8.40%). Together, they hold 47.36% of Sionna Therapeutics’s total shares outstanding.

Does Blackrock own Sionna Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Sionna Therapeutics.

Who is Sionna Therapeutics’s biggest shareholder by percentage of total assets invested?

Enavate sciences gp is Sionna Therapeutics’s biggest shareholder by percentage of total assets invested, with 22.25% of its assets in 2.48M Sionna Therapeutics shares, valued at 72.88M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools